- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01082978
Portable Health Files Improve Quality of Care and Health Outcomes: a Randomized Controlled Trial (PHF-RCT)
A Randomized Controlled Trial of Portable Electronic(USB)and Paper Medical Records as an Adjunct to Usual Care (Portable Health File RCT): an Evaluation of Short Term Quality Measures and Long-term Clinical Outcomes
The PHF trial will assess the acceptability and long term outcomes resulting from the usage of electronic (carried by the patient on a USB memory device) and paper portable health files in a population with high intensity use of medical services. The rationale is that use of the portable health files provides a conduit of direct communication among health care providers of a patient's important health care information and this leads to better care and patient outcomes.
Primary hypothesis: Addition of a patient-held portable health file (PHF) to usual care improves patient outcome and quality-of-life compared to usual care alone.
Secondary hypothesis: Addition of patient-held portable health file (PHF) to usual care is acceptable and satisfactory to patients and their health care providers.
Study Overview
Status
Intervention / Treatment
Detailed Description
A common problem faced by patients and clinicians in our health system is continuity of care and 'clinical handovers'. Few medical record technologies, paper or electronic, top down or bottom up, have been evaluated in a randomised clinical outcome trial to determine the clinical benefits and costs of 'shared' medical and health information. Furthermore, although there are many studies that have evaluated processes of care only a minority do so within a randomized design. Given that any difference is, possibly, small to moderate in magnitude, and given confounders, the use of a randomisation is an essential design requirement.
The first 12 months of the trial constitutes Stage 1 whose primary objective is to describe the acceptability and satisfaction of the our Portable Health Files, and other key process measures. The subsequent 36 months constitutes Stage 2 whose primary objective it to compare important clinical outcomes. The assigned treatment (i.e., the e-PHF or p-PHF) will be used for 4 years total.
To take into account a probable lag effect of the interventions, patients will also be followed for an additional 3 years beyond the conclusion of the randomised trial to see if there are any longer-term effects.
The trial is un-blinded so there will be a potential for bias in trial conduct and a potential for ascertainment bias in the determination of important clinical outcomes and quality-of-life. To reduce clinical outcome ascertainment bias a blinded Adjudication Committee will make the determination which out-of-hospital events are "serious". The other primary outcomes: mortality and all overnight hospitalizations are objective outcomes and are not subject to ascertainment bias.
Secondary outcomes include quality of life, quality measures uptake, investigations, medication use, medication errors, and adverse drug reactions. Utilities and costs will also be collected for cost-effectiveness analysis. Patient and provider acceptability and satisfaction with the PHFs will be also collected.
All primary analyses will be undertaken masked to randomized arm allocation.
Most secondary analyses including quality of life, quality measures uptake, investigations, medication use, medication errors, and adverse drug reactions, health utilities, health care utilisation and health care costs will also be undertaken masked to randomized arm allocation.
This Adjudication Committee will also monitor trial safety and scientific integrity.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- St George Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be of age 60 or greater
- Patients living independently in the community. Hostel care is acceptable, but patients that are not independent requiring full nursing home care are excluded.
- Subjects must have had six medical practitioner visits in the previous 12 months
- Subjects must have at least two of the following confirmed chronic diseases that require prescription oral or parenteral drug treatment or surgery and requiring at least annual specialist consultation: cardiovascular, respiratory, endocrine, renal, neurologic, gastrointestinal, hepatic, genitourinary, haematologic. infective, rheumatic, inflammatory, immunologic or neoplastic disease.
6. Subject's GP must have access to a computer during the consultation visit. 7. Subjects must have at least two medical specialists at least one of whom has access to a computer during the consultation visit.
8. Subjects must be able to understand the purpose of the trial and undergo full and valid informed consent.
Exclusion Criteria:
- Life expectancy of less than 12 months.
- Inability to carry a paper PHF or e-PHF and having no care-giver willing and able to accomplish same.
- Mentally unable to undertake valid informed consent.
- Patients who are not independent in the community, that cannot mobilise to see a specialist or requiring full nursing home care
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Electronic (USB) Portable Health File
Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software.
The portable health files contained core medical data which functions as a subset of a comprehensive medical record.
The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
|
Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software.
The portable health files contained core medical data which functions as a subset of a comprehensive medical record.
The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
Other Names:
|
Experimental: Paper Portable Health File
Patients randomized to this arm of the trial will be given the paper Portable Health File.
The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record.
This paper-based portable health file is updated by health care providers at each visit.
The PHF can also be updated by patient between visits.
|
Patients randomized to this arm of the trial will be given the paper Portable Health File.
The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record.
This paper-based portable health file is updated by health care providers at each visit.
The PHF can also be updated by patient between visits.
Other Names:
|
No Intervention: Usual standard of care
Patients randomized to this arm of the trial will not be given a Portable Health File.
This arm is the concurrent control comparator arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Combined endpoint of deaths, hospitalisations (excepting day only hospitalisations), and serious out-of-hospital events
Time Frame: 48 months + 36 month extension
|
The primary outcome is the total number of important clinical events (all hospitalisations except same-day hospitalisations, all serious out-of-hospital events and deaths). See above: The assigned treatment (i.e., the e-PHF or p-PHF) will be used for 4 years total. Patients will also be followed for an additional 3 years beyond the conclusion of the randomised trial to see if there are any longer-term lag effects. |
48 months + 36 month extension
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life
Time Frame: every 12 months for 48 months
|
SF-36 and EQ-5D
|
every 12 months for 48 months
|
health service utilisation and health care costs
Time Frame: every 12 months for 48 months
|
Emergency Department encounters, General Practitioner and Specialist Encounters via record linkage, and their estimated costs by MBS and other costs data
|
every 12 months for 48 months
|
medication errors, duplicative investigations
Time Frame: every 12 months for 48 months
|
Questionnaire, Self-report PROs and CROs
|
every 12 months for 48 months
|
clinical workflow
Time Frame: every 6 months for 2 years then every 12 months until 48 months
|
Questionnaire, Self-report PROs and CROs
|
every 6 months for 2 years then every 12 months until 48 months
|
subject and health care provider acceptability and satisfaction with portable health files (PHF)
Time Frame: every 3 months for 12 months then every 6 months 24 months then every 12 months until 48 months
|
Questionnaire, Self-report PROs and CROs
|
every 3 months for 12 months then every 6 months 24 months then every 12 months until 48 months
|
guidelines uptake and documentation
Time Frame: every 6 months for 24 months then every 12 months until 48 months
|
Questionnaire, Self-report PROs and CROs
|
every 6 months for 24 months then every 12 months until 48 months
|
health literacy
Time Frame: every 12 months until 48 months
|
Questionnaire, Self-report PROs
|
every 12 months until 48 months
|
information technology and computer expertise
Time Frame: every 6 months for 24 months then every 12 months until 48 months
|
Questionnaire, Self-report PROs
|
every 6 months for 24 months then every 12 months until 48 months
|
adverse events
Time Frame: every 3 months for 24 months then every 6 months until 48 months
|
Questionnaire, Self-report PROs
|
every 3 months for 24 months then every 6 months until 48 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Marissa ND Lassere, MBBS PhD, St George Hospital and Univeristy of NSW
- Principal Investigator: Kent R Johnson, MD, Newcastle University
- Principal Investigator: George Rubin, MD, South East Sydney Area Health Service
- Principal Investigator: Anthony Sara, MBBS MBA, South East Sydney Area Health Service
- Principal Investigator: Andrew Parle, BSc (Hons) PhD, Consultant
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PHF-06-124-ML
- NHMRC 455467 (Other Grant/Funding Number: NHMRC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Personal Health Records
-
Weill Medical College of Cornell UniversityMaimonides Medical Center; New York State Department of HealthCompleted
-
University of IowaCompletedCardiovascular Diseases | Personal Health Records | Pharmaceutical Care | Mobile AppsUnited States
-
Weill Medical College of Cornell UniversityThe Commonwealth Fund; New York State Department of Health; Taconic Health Information... and other collaboratorsCompletedElectronic Health Records | Quality of Health CareUnited States
-
University Hospital, GrenobleUnknown
-
University of UtahAgency for Healthcare Research and Quality (AHRQ)Completed
-
Seoul National University Bundang HospitalEnrolling by invitationPersonal Health RecordKorea, Republic of
-
EnzymotecBiostime, Inc. (Guangzhou)CompletedHealth Behavior | Personal SatisfactionChina
-
Unilever IsraelUnknownPersonal Experience and Personal Initiation Program | Health Prevention Activities | Impact on PatientsIsrael
-
University of BolognaUnknownHealth Behavior | Personal Satisfaction
-
Yale UniversityNational Library of Medicine (NLM)Not yet recruitingPersonal Health Information | Incarcerated IndividualsUnited States
Clinical Trials on Electronic (USB) Portable Health File
-
Manchester University NHS Foundation TrustCardiff University; University of Manchester; National Institute for Health Research... and other collaboratorsCompletedModerate or Severe Vision Impairment, Both EyesUnited Kingdom
-
Ohio State UniversityRecruitingCognitive DeclineUnited States
-
Weill Medical College of Cornell UniversityCompleted
-
University of North Carolina, Chapel HillCompleted
-
Shenzhen Smoore Technology LimitedWithdrawn
-
M.D. Anderson Cancer CenterRecruitingMetastatic Malignant Neoplasm in the SpineUnited States
-
Mayo ClinicCompletedMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell... and other conditionsUnited States
-
Augusta UniversityAgency for Healthcare Research and Quality (AHRQ); Cerner Corporation; The Institute...CompletedHypertensionUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States